Circulating angiogenic factors and HIV among pregnant women in Zambia: a nested case-control study.
Adult
Angiogenesis Inducing Agents
Biomarkers
/ blood
Case-Control Studies
Endoglin
/ blood
Female
HIV Infections
/ blood
Humans
Placenta
/ blood supply
Placenta Growth Factor
/ blood
Pregnancy
Pregnancy Complications, Infectious
/ blood
Pregnancy Outcome
/ epidemiology
Premature Birth
/ epidemiology
Vascular Endothelial Growth Factor A
/ blood
Vascular Endothelial Growth Factor Receptor-1
/ blood
Zambia
/ epidemiology
HIV
Placental growth factor
Preterm birth
Soluble fms-like tyrosine kinase-1
Stillbirth
Journal
BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799
Informations de publication
Date de publication:
28 Jul 2021
28 Jul 2021
Historique:
received:
15
10
2020
accepted:
24
06
2021
entrez:
29
7
2021
pubmed:
30
7
2021
medline:
18
11
2021
Statut:
epublish
Résumé
Maternal HIV increases the risk of adverse birth outcomes including preterm birth, fetal growth restriction, and stillbirth, but the biological mechanism(s) underlying this increased risk are not well understood. We hypothesized that maternal HIV may lead to adverse birth outcomes through an imbalance in angiogenic factors involved in the vascular endothelial growth factor (VEGF) signaling pathway. In a case-control study nested within an ongoing cohort in Zambia, our primary outcomes were serum concentrations of VEGF-A, soluble endoglin (sEng), placental growth factor (PlGF), and soluble fms-like tyrosine kinase-1 (sFLT-1). These were measured in 57 women with HIV (cases) and 57 women without HIV (controls) before 16 gestational weeks. We used the Wilcoxon rank-sum and linear regression controlling for maternal body mass index (BMI) and parity to assess the difference in biomarker concentrations between cases and controls. We also used logistic regression to test for associations between biomarker concentration and adverse pregnancy outcomes (preeclampsia, preterm birth, small for gestational age, stillbirth, and a composite of preterm birth or stillbirth). Compared to controls, women with HIV had significantly lower median concentrations of PlGF (7.6 vs 10.2 pg/mL, p = 0.02) and sFLT-1 (1647.9 vs 2055.6 pg/mL, p = 0.04), but these findings were not confirmed in adjusted analysis. PlGF concentration was lower among women who delivered preterm compared to those who delivered at term (6.7 vs 9.6 pg/mL, p = 0.03) and among those who experienced the composite adverse birth outcome (6.2 vs 9.8 pg/mL, p = 0.02). Median sFLT-1 concentration was lower among participants with the composite outcome (1621.0 vs 1945.9 pg/mL, p = 0.04), but the association was not significant in adjusted analysis. sEng was not associated with either adverse birth outcomes or HIV. VEGF-A was undetectable by Luminex in all specimens. We present preliminary findings that HIV is associated with a shift in the VEGF signaling pathway in early pregnancy, although adjusted analyses were inconclusive. We confirm an association between angiogenic biomarkers and adverse birth outcomes in our population. Larger studies are needed to further elucidate the role of HIV on placental angiogenesis and adverse birth outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Maternal HIV increases the risk of adverse birth outcomes including preterm birth, fetal growth restriction, and stillbirth, but the biological mechanism(s) underlying this increased risk are not well understood. We hypothesized that maternal HIV may lead to adverse birth outcomes through an imbalance in angiogenic factors involved in the vascular endothelial growth factor (VEGF) signaling pathway.
METHODS
METHODS
In a case-control study nested within an ongoing cohort in Zambia, our primary outcomes were serum concentrations of VEGF-A, soluble endoglin (sEng), placental growth factor (PlGF), and soluble fms-like tyrosine kinase-1 (sFLT-1). These were measured in 57 women with HIV (cases) and 57 women without HIV (controls) before 16 gestational weeks. We used the Wilcoxon rank-sum and linear regression controlling for maternal body mass index (BMI) and parity to assess the difference in biomarker concentrations between cases and controls. We also used logistic regression to test for associations between biomarker concentration and adverse pregnancy outcomes (preeclampsia, preterm birth, small for gestational age, stillbirth, and a composite of preterm birth or stillbirth).
RESULTS
RESULTS
Compared to controls, women with HIV had significantly lower median concentrations of PlGF (7.6 vs 10.2 pg/mL, p = 0.02) and sFLT-1 (1647.9 vs 2055.6 pg/mL, p = 0.04), but these findings were not confirmed in adjusted analysis. PlGF concentration was lower among women who delivered preterm compared to those who delivered at term (6.7 vs 9.6 pg/mL, p = 0.03) and among those who experienced the composite adverse birth outcome (6.2 vs 9.8 pg/mL, p = 0.02). Median sFLT-1 concentration was lower among participants with the composite outcome (1621.0 vs 1945.9 pg/mL, p = 0.04), but the association was not significant in adjusted analysis. sEng was not associated with either adverse birth outcomes or HIV. VEGF-A was undetectable by Luminex in all specimens.
CONCLUSIONS
CONCLUSIONS
We present preliminary findings that HIV is associated with a shift in the VEGF signaling pathway in early pregnancy, although adjusted analyses were inconclusive. We confirm an association between angiogenic biomarkers and adverse birth outcomes in our population. Larger studies are needed to further elucidate the role of HIV on placental angiogenesis and adverse birth outcomes.
Identifiants
pubmed: 34320947
doi: 10.1186/s12884-021-03965-5
pii: 10.1186/s12884-021-03965-5
pmc: PMC8317322
doi:
Substances chimiques
Angiogenesis Inducing Agents
0
Biomarkers
0
Endoglin
0
Vascular Endothelial Growth Factor A
0
Placenta Growth Factor
144589-93-5
Vascular Endothelial Growth Factor Receptor-1
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
534Subventions
Organisme : FIC NIH HHS
ID : K01 TW010857
Pays : United States
Organisme : NIH HHS
ID : K01 TW010857
Pays : United States
Organisme : NIH HHS
ID : T32 HD075731
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009340
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Int J Mol Sci. 2015 Aug 13;16(8):19009-26
pubmed: 26287164
FASEB J. 2018 Jun;32(6):2934-2949
pubmed: 29401587
Hum Reprod. 2016 Dec;31(12):2681-2688
pubmed: 27664209
Acta Histochem. 2007;109(4):257-65
pubmed: 17574656
Obstet Gynecol. 2007 Jun;109(6):1316-24
pubmed: 17540803
Trop Med Int Health. 2017 May;22(5):604-613
pubmed: 28214384
Am J Obstet Gynecol. 2012 Feb;206(2):108-12
pubmed: 22118964
Placenta. 2004 Feb-Mar;25(2-3):127-39
pubmed: 14972445
Gates Open Res. 2019 Sep 4;3:1533
pubmed: 32161903
Am J Obstet Gynecol. 2012 Feb;206(2):113-8
pubmed: 22177186
Am J Obstet Gynecol. 2018 Feb;218(2S):S630-S640
pubmed: 29422205
Gates Open Res. 2018 Dec 4;2:25
pubmed: 30706053
Acta Obstet Gynecol Scand. 2011 Nov;90(11):1244-51
pubmed: 21568945
J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):94-102
pubmed: 30272633
Am J Obstet Gynecol. 2014 Sep;211(3):247.e1-7
pubmed: 24631439
PLoS One. 2012;7(2):e32509
pubmed: 22389705
Cardiovasc J Afr. 2012 Apr;23(3):153-9
pubmed: 22555639
Am J Epidemiol. 2011 Mar 15;173(6):630-9
pubmed: 21317220
J Matern Fetal Neonatal Med. 2010 Dec;23(12):1384-99
pubmed: 20459337
Am J Obstet Gynecol. 2017 Dec;217(6):684.e1-684.e17
pubmed: 29031892
Lancet HIV. 2016 Jan;3(1):e33-48
pubmed: 26762992
Int J Gynaecol Obstet. 2019 Jan;144(1):9-15
pubmed: 30267538
Cardiovasc J Afr. 2013 Jun;24(5):174-9
pubmed: 24217170
J Clin Endocrinol Metab. 2011 Sep;96(9):E1444-51
pubmed: 21715541